

PRESS RELEASE Stockholm, January 30, 2023

ADDvise announces preliminary result for 2022 which is stronger than expected

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations.

SEK million	Q4 2022	Q4 2021	Jan-Dec 2022	Jan-Dec 2021
Net sales	319	155	948	466
Gross profit	204	71	563	214
Gross margin %	63,9%	45,5%	59,3%	45,9%
EBITDA	89	19	184	57
EBITDA margin %	28,1%	12,5%	19,4%	12,3%
Adjusted EBITDA	85	19	174	57
Adjusted EBITDA margin %	26,6%	12,3%	18,3%	12,2%

The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million.

The financial targets for the same period, as earlier communicated, are adjusted EBITDA pro forma SEK 200 million and net sales pro forma SEK 1 billion.

Consequently, the financial targets for 2022 are exceeded.

The financial information provided above is preliminary and unaudited.

ADDvise Group's Year-End Report is published February 23, 2023.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 (0)765-25 90 71
rikard.akhtarzand@addvisigroup.se

Important information:

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was released for publication on January 30, 2023 at 15:30 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business units: Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business—both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market, and Mangold Fondkommission AB, +46 (0)8-503 015 50, CA@mangold.se, is the company's certified adviser. Further information is available at www.addvisegroup.com.